[Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
Sixty cases of Parkinson's disease were treated with piribedil alone (dose : 274 mg/day, duration : 20,4 months). The overall clinical improvement, confirmed by recordings of tremor and EMG, was 34%, tremor being improved of 59%. Before treatment, an intravenous test does of piribedil with recording made it possible to predict the effectiveness of oral treatment. Side-effects (vasomotor, digestive, psychiatric) were moderate. Orthostatic hypotension, dyskinesia and fluctuations were exceptional. The basic indication for piribedil lies in forms of recent onset in which tremor predominates, patients in whom L-dopa is contraindicated and a certain number in whom the latter has failed (tremor, fluctuating action).
D000284:Administration, Oral; D000322:Adrenergic Agonists / Q000627:therapeutic use*; D000368:Aged; D004359:Drug Therapy, Combination; D004576:Electromyography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010879:Piperazines / Q000627:therapeutic use*; D010891:Piribedil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011954:Receptors, Dopamine / Q000502:physiology
D000322:Adrenergic Agonists; D010879:Piperazines; D011954:Receptors, Dopamine; D007980:Levodopa; D010891:Piribedil
Le piribédil, agoniste dopaminergique. Etude clinique et électrophysiologique prolongée chez 60 parkinsoniens.